Ten-Year Registration Validity and Re-Registration Rules for Medical Devices in Egypt

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The validity period of an Egyptian registration licence is 10 years, and re-registration likewise occurs once every 10 years. Two figures anchor the timeline management: the initial acceptance must fall within the first 3 months of the last year of the registration licence validity, and once the re-registration documents are accepted, if the data provided match the administration’s own data, the company receives a one-year release period from the date of document acceptance. One additional rule carries high value: for locally manufactured devices and devices imported from non-reference countries, no re-evaluation by the Scientific Committee is required at re-registration, provided the safety department has reported that the documents have been accepted, no regulatory measures have occurred for the device, and the registered device is unchanged in composition, intended purpose, design and classification.

2. Legal basis

The validity, window, release and exemption rules are distributed across the registration guideline and the import approval guideline.

RegulationReferencePublication dateProvision
Regulatory Guideline for Registration Procedures of Imported and Locally Manufactured Medical Devices Holding International Quality CertificatesEDREX: GL.CAMD.002 Version 2September 2025Section 9 (registration report valid for 10 years)
Regulatory Guideline for Registration Procedures of Imported and Locally Manufactured Medical Devices Holding International Quality CertificatesEDREX: GL.CAMD.002 Version 2September 2025Section 10 (re-registration procedure and committee exemption conditions)
Regulatory Guideline for Registration Procedures of Imported and Locally Manufactured Medical Devices Holding International Quality CertificatesEDREX: GL.CAMD.002 Version 2September 2025Section 11, item 7 (validity period and acceptance window)
Regulatory Guideline for Issuance of Import Approvals for Various Types of Medical DevicesEDREX: GL.CAMD.007 Version 2September 2025Section 8.1.1, Special guidance, items 1 and 2

3. Expert insights

Insight 1: the 10 years run from the registration date, and registration and re-registration share the same window rule.

Section 11, item 7 provides that the registration licence expires ten years after the date of registration, and that the initial acceptance of the request must fall within the first 3 months of the last year of the registration licence validity. The period from the end of year 9 through the first 3 months of year 10 is therefore the only compliant filing window for re-registration. Missing the window places the licence into a lapsed state.

Insight 2: the one-year release period solves the practical problem of importing while re-registration is pending.

GL.CAMD.007 Section 8.1.1, Special guidance, item 2: for devices submitted for re-registration, the Central Registration Administration provides a document acceptance number; if the data submitted to the administration match the company’s own data, the company receives a one-year release period from the date of document acceptance. Item 1 addresses new registration: as a rule, no release is granted before the registration notice is issued, except in two situations (a change in raw materials relative to the registered items, or a change confined to the applicant’s name with other changes within the variation list), in which case a one-year release period runs from the date of acceptance.

Insight 3: the committee exemption has four conditions, all of which must be met simultaneously.

Section 10 provides that locally manufactured devices and devices imported from non-reference countries require no re-evaluation by the Scientific Committee at re-registration, subject to: (1) receipt of a safety department report stating that the documents have been accepted; (2) no regulatory measures have occurred for the device; (3) no change in composition of the registered device; and (4) no change in intended purpose, design or classification. The four are parallel conditions; failing any one returns the file to the committee pathway. For Chinese manufacturers (non-reference country imports), this rule is the only route to bypass the committee at the re-registration stage.

Insight 4: re-registration still requires a full dossier and the service fee.

Section 10: the applicant must submit the re-registration dossier according to the required document list, and the service fee is collected in accordance with the decision issued by the Chairman of the EDA. Re-registration is therefore not an automatic renewal but a complete application in its own right.

Insight 5: re-registration also requires the original registration licence.

Annex 1, item 7(K): in re-registration cases, the original registration licence must be submitted. Companies must safeguard the original throughout the ten-year cycle; losing it will obstruct the filing of the re-registration application.

Insight 6: re-registration requires a real-time stability study.

Section 6, item Second: devices submitted for re-registration must provide a real-time stability study. Read together with the stability trigger rules in Section 10 (studies never submitted are assessed at re-registration), the data collection for the real-time study should begin at first registration, not a decade later.

Insight 7: licence expiry and the one-year import approval validity are two different cycles.

The registration licence runs for 10 years; the import approval for 1 year; the annual import plan for 1 year. Expiry management for the three must be maintained in separate ledgers, because a registration licence that is still valid does not by itself permit importing.

4. Practical recommendations

The following measures keep the ten-year cycle under control.

  1. Set a re-registration filing reminder at the end of year 9: the window is the first 3 months of the final year.
  2. Aim for the committee exemption: confirm no changes in composition, intended purpose, design or classification, and secure the safety department acceptance report.
  3. Safeguard the original registration licence: it is mandatory for filing re-registration.
  4. Start the real-time stability study at first registration to accumulate data for re-registration ten years later.
  5. Record the document acceptance number after filing: it underpins the one-year release period.
  6. Budget the service fee into re-registration planning, according to the current EDA Chairman decision.
  7. Maintain three separate ledgers for the registration licence, import approvals and annual plans.

5. Verification checklist

  • □ The issuance date of the registration licence is recorded and the 10-year expiry date is back-planned
  • □ A reminder is set for the re-registration filing window (first 3 months of the last year)
  • □ The four exemption conditions are confirmed item by item (safety department report / no regulatory measures / composition / intended purpose, design, classification)
  • □ The original registration licence is available
  • □ The real-time stability study is complete
  • □ The document acceptance number is recorded and the one-year release period is built into the import plan
  • □ Three validity ledgers (10 years / 1 year / 1 year) are maintained separately

Regulatory information verified as of October 29, 2026. The validity and re-registration rules in this article follow the current text of EDREX: GL.CAMD.002 Version 2, Sections 9, 10 and 11; the release period rules follow EDREX: GL.CAMD.007 Version 2, Section 8.1.1, Special guidance.

  • Egypt local support: GRZAN assists manufacturers from the Chinese mainland and overseas with EDA medical device registration, import approval and variation applications, including registration applicant pathway design (importing company, local factory, or Scientific Office), preparation for Scientific Committee evaluation, demonstration of free sale certificate routes from reference countries, Arabic labelling and instructions-for-use localization, and the setup of vigilance and periodic reporting systems.
  • Service capabilities: product classification and risk grading (devices Class I–III, IVD Class A–D), registration and re-registration, applicability assessment for system registration and bundled registration, three-way variation classification, import approval and annual import plans, and support for vigilance reporting and field safety corrective actions.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail